Guidelines on the Use of Intravenous Immune Globulin for Hematologic Conditions

Transfusion Medicine Reviews

Volumn 21, Issue SUPPL. 1, 2007, Pages

  Anderson, David ^a   Ali, Kaiser ^a   Blanchette, Victor ^a   Brouwers, Melissa ^a   Couban, Stephen ^a   Radmoor, Paula ^a   Huebsch, Lothar ^a   Hume, Heather ^a   McLeod, Anne ^a   Meyer, Ralph ^a   Moltzan, Catherine ^a   Nahirniak, Susan ^a   Nantel, Stephen ^a   Pineo, Graham ^a   Rock, Gail ^a  

^a IVIG Hematology and Neurology Expert Panels ^*  (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; ANTIBIOTIC AGENT; AZATHIOPRINE; BLOOD CLOTTING FACTOR 8 CONCENTRATE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DANAZOL; DESMOPRESSIN; DEXAMETHASONE; ERYTHROPOIETIN; ETOPOSIDE; GLUCOCORTICOID; GRANULOCYTE COLONY STIMULATING FACTOR; HEPARIN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; PREDNISONE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; RHESUS D ANTIBODY; RITUXIMAB; STEROID; THYMOCYTE ANTIBODY; UNINDEXED DRUG; ZIDOVUDINE;

ACUTE GRAFT VERSUS HOST DISEASE; ADJUVANT THERAPY; ADULTHOOD; APLASTIC ANEMIA; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; BLEEDING; BLOOD BANK; BLOOD TRANSFUSION REACTION; BONE MARROW TRANSPLANTATION; CANADA; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSENSUS; CONTINUOUS INFUSION; CRYOPRECIPITATE; DOSAGE SCHEDULE COMPARISON; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG INDICATION; DRUG MEGADOSE; DRUG USE; DRUG WITHDRAWAL; ERYTHROCYTE APLASIA; ERYTHROCYTE TRANSFUSION; EVIDENCE BASED MEDICINE; FETAL NEONATAL ALLOIMUNE THROMBOCYTOPENIA; FETUS DISEASE; HEALTH CARE PERSONNEL; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOLYSIS; HEMOLYTIC ANEMIA; HEMOLYTIC UREMIC SYNDROME; HEMOPHAGOCYTIC SYNDROME; HEMOPHILIA; HEMOPHILIA A; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPOGAMMAGLOBULINEMIA; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOADSORPTION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTION PREVENTION; INFECTIOUS COMPLICATION; KIDNEY DISEASE; MEDICAL EXPERT; MONOTHERAPY; MOTHER; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NEWBORN DISEASE; NEWBORN HEMOLYTIC DISEASE; NEWBORN PERIOD; OFF LABEL DRUG USE; PHOTOTHERAPY; PLASMAPHERESIS; POSTTRANSFUSION PURPURA; PRACTICE GUIDELINE; PURPURA; RECOMMENDED DRUG DOSE; SICKLE CELL ANEMIA; SPLENECTOMY; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT DURATION; TREATMENT RESPONSE; VEIN OCCLUSION; VIRUS INFECTION; VON WILLEBRAND DISEASE;

CANADA; EVIDENCE-BASED MEDICINE; HEMATOLOGIC DISEASES; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; PRACTICE GUIDELINES; SUBSTANCE-RELATED DISORDERS;

EID: 33947727249     PISSN: 08877963     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tmrv.2007.01.001     Document Type: Article

References (148)

1. Feasby TE: Appropriateness of IVIG-hematology summaries (unpublished).
2. Biotext Science Information Consultants. A systematic literature review and report on the efficacy of intravenous immunoglobulin therapy and its risks. Final Report v04 (2004), Australian National Blood Authority. www.nba.gov.au/pubs.htm
3. Chalmers Research Institute: IVIG systematic reviews. (unpublished)
4. Pierce L.R., and Jain N. Risks associated with the use of intravenous immunoglobulin. Transfus Med Rev 17 (2003) 241-251
5. Phillips B., Ball C., Sackett D., et al. Levels of evidence (2002). www.eboncall.org/content/levels.html
6. Browman G.P., Newman T.E., Mohide E.A., et al. Progress of clinical oncology guidelines development using the practice guidelines development cycle: The role of practitioner feedback. J Clin Oncol 16 (1998) 1226-1231
7. Crenier L., Ducobu J., des Grottes J.M., et al. Low response to high-dose intravenous immunoglobulin in the treatment of acquired factor VIII inhibitor. Br J Haematol 95 (1996) 750-753
8. Dykes A.C., Walker I.D., Lowe G.D., et al. Combined prednisolone and intravenous immunoglobulin treatment for acquired factor VIII inhibitors: A 2-year review. Haemophilia 7 (2001) 160-163
9. Boughton B.J., Jackson N., Lim S., et al. Randomized trial of intravenous immunoglobulin prophylaxis for patients with chronic lymphocytic leukaemia and secondary hypogammaglobulinaemia. Clin Lab Haematol 17 (1995) 75-80
10. Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia. Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. N Engl J Med 319 (1988) 902-907
11. Chapel H., Dicato M., Gamm H., et al. Immunoglobulin replacement in patients with chronic lymphocytic leukaemia: A comparison of 2 dose regimes. Br J Haematol 88 (1994) 209-212
12. Gamm H., Huber C., Chapel H., et al. Intravenous immune globulin in chronic lymphocytic leukaemia. Clin Exp Immunol 97 (1994) 17-20 (Suppl 1)
13. Griffiths H., Brennan V., Lea J., et al. Crossover study of immunoglobulin replacement therapy in patients with low-grade B-cell tumors. Blood 73 (1989) 366-368
14. Molica S., Musto P., Chiurazzi F., et al. Prophylaxis against infections with low-dose intravenous immunoglobulins (IVIG) in chronic lymphocytic leukemia. Results of a crossover study. Haematologica 81 (1996) 121-126
15. Chapel H.M., Lee M., Hargreaves R., et al. Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma. Lancet 343 (1994) 1059-1063
16. Hargreaves R.M., Lea J.R., Holt J., et al. Infection, immune responses and IV immunoglobulin infection prophylaxis in myeloma. (abstract). Br J Cancer 66 (1992) 261 (Suppl XVII)
17. Schedel I. Intravenous immunoglobulin replacement in secondary antibody deficiency syndrome. Diagn Intensivther 7 (1982) 254-263
18. Gebauer E., Tomic J., and Stevanovic S. Intravenous immunoglobulin in the treatment of infections in children with acute leukemias. Med Pregl 47 (1994) 52-55
19. Gimesi A., Eibl M., Koos R., et al. Immunoglobulin prophylaxis during intensive treatment of acute lymphoblastic leukemia in children. Acta Paediatr Hung 32 (1992) 115-125
20. Sumer T., Abumelha A., al-Mulhim I., et al. Treatment of fever and neutropenia with antibiotics versus antibiotics plus intravenous gammaglobulin in childhood leukemia. Eur J Pediatr 148 (1989) 401-402
21. Hayakawa F., Imada K., Towatari M., et al. Life-threatening human parvovirus B19 infection transmitted by intravenous immune globulin. Br J Haematol 118 (2002) 1187-1189
22. Ballester O.F., Saba H.I., Moscinski L.C., et al. Pure red cell aplasia: Treatment with intravenous immunoglobulin concentrate. Semin Hematol 29 (1992) 106-108 (3 Suppl 2)
23. Casadevall N., Lacombe C., and Varet B. Erythroblastopenia: Chronic idiopathic or associated with chronic lymphoid leukemia. Value of cultures of erythroblastic progenitors and therapeutic strategy. Presse Med 22 (1993) 1079-1086
24. Castelli R., Vismara A., Pavia G., et al. Relapsing pure red cell aplasia associated with B-cell chronic lymphocytic leukemia successfully treated by intravenous immunoglobulin concentrate. Ann Ital Med Int 17 (2002) 47-50
25. Clauvel J.P., Vainchenker W., Herrera A., et al. Treatment of pure red cell aplasia by high dose intravenous immunoglobulins. Br J Haematol 55 (1983) 380-382
26. Cobcroft R. Pure red cell aplasia associated with small lymphocytic lymphoma. Br J Haematol 113 (2001) 260
27. Ilan Y., and Naparstek Y. Pure red cell aplasia associated with systemic lupus erythematosus: Remission after a single course of intravenous immunoglobulin. Acta Haematol 89 (1993) 152-154
28. Huang J.L., Hung I.J., Chen L.C., et al. Successfully treated sulphasalazine-induced fulminant hepatic failure, thrombocytopenia and erythroid hypoplasia with intravenous immunoglobulin. Clin Rheumatol 17 (1998) 349-352
29. Larroche C., Mouthon L., Casadevall N., et al. Successful treatment of thymoma-associated pure red cell aplasia with intravenous immunoglobulins. Eur J Haematol 65 (2000) 74-76
30. Mant M.J. Chronic idiopathic pure red cell aplasia: Successful treatment during pregnancy and durable response to intravenous immunoglobulin. J Intern Med 236 (1994) 593-595
31. McGuire W.A., Yang H.H., Bruno E., et al. Treatment of antibody-mediated pure red-cell aplasia with high-dose intravenous gamma globulin. N Engl J Med 317 (1987) 1004-1008
32. Needleman S.W. Durable remission of pure red cell aplasia after treatment with high-dose intravenous gammaglobulin and prednisone. Am J Hematol 32 (1989) 150-152
33. Ohashi K., Akiyama H., Takamoto S., et al. Treatment of pure red cell aplasia after major ABO-incompatible bone marrow transplantation resistant to erythropoietin. Bone Marrow Transplantation Team. Bone Marrow Transplant 13 (1994) 335-336
34. Roychowdhury D.F., and Linker C.A. Pure red cell aplasia complicating an ABO-compatible allogeneic bone marrow transplantation, treated successfully with antithymocyte globulin. Bone Marrow Transplant 16 (1995) 471-472
35. Amiot L., Langanay T., Drenou B., et al. Spontaneous recovery from severe parvovirus B19 pure red cell aplasia, in a heart transplant recipient, as demonstrated by marrow culture. Hematol Cell Ther 40 (1998) 71-73
36. Koduri P.R., Kumapley R., Khokha N.D., et al. Red cell aplasia caused by parvovirus B19 in AIDS: Use of I.V. immunoglobulin. Ann Hematol 75 (1997) 67-68
37. Koduri P.R., Kumapley R., Valladares J., et al. Chronic pure red cell aplasia caused by parvovirus B19 in AIDS: Use of intravenous immunoglobulin-a report of 8 patients. Am J Hematol 61 (1999) 16-20
38. Kondo H., Mori A., Watanabe J., et al. Pure red cell aplasia associated with parvovirus B19 infection in T-large granular lymphocyte leukemia. Leuk Lymphoma 42 (2001) 1439-1443
39. Wong T.Y., Chan P.K., Leung C.B., et al. Parvovirus B19 infection causing red cell aplasia in renal transplantation on tacrolimus. Am J Kidney Dis 34 (1999) 1132-1136
40. Federici A.B., Stabile F., Castaman G., et al. Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance: Comparison of 3 different therapeutic approaches. Blood 92 (1998) 2707-2711
41. Bergen G.A., Sakalosky P.E., and Sinnott J.T. Transient aplastic anemia caused by parvovirus B19 infection in a heart transplant recipient. J Heart Lung Transplant 15 (1996) 843-845
42. Bourantas K., Makrydimas G., Georgiou I., et al. Aplastic anemia. Report of a case with recurrent episodes in consecutive pregnancies. J Reprod Med 42 (1997) 672-674
43. Chen S.H., Liang D.C., and Lin M. Treatment of platelet alloimmunization with intravenous immunoglobulin in a child with aplastic anemia. Am J Hematol 49 (1995) 165-166
44. Chen R.L., Lin K.H., Lin D.T., et al. Immunomodulation treatment for childhood virus-associated haemophagocytic lymphohistiocytosis. Br J Haematol 89 (1995) 282-290
45. Kapoor N., Hvizdala E., and Good R.A. High dose intravenous gammaglobulin as an approach to treatment of antibody mediated pancytopenia. Br J Haematol 69 (1988) 98-99
46. De Lord C., Marsh J.C., Smith J.G., et al. Fatal autoimmune pancytopenia following bone marrow transplantation for aplastic anaemia. Bone Marrow Transplant 18 (1996) 237-239
47. Lutz P., Gallais C., Albert A., et al. Use of intravenous immunoglobulins (IVIg) to treat a child with pancytopenia and hypoplastic marrow. Ann Hematol 65 (1992) 199-200
48. Salim S., and Salim K.A. Chicken pox induced pancytopenia and prompt response to high dose intravenous immunoglobulin. J Assoc Physicians India 40 (1992) 689-690
49. Sherer Y., Levy Y., Fabbrizzi F., et al. Treatment of hematologic disorders other than immune thrombocytopenic purpura with intravenous immunoglobulin (IVIg)-report of 7 cases and review of the literature. Eur J Intern Med 11 (2000) 85-88
50. Flores G., Cunningham-Rundles C., Newland A.C., et al. Efficacy of intravenous immunoglobulin in the treatment of autoimmune hemolytic anemia: Results in 73 patients. Am J Hematol 44 (1993) 237-242
51. Bussel J., Lalezari P., Hilgartner M., et al. Reversal of neutropenia with intravenous gammaglobulin in autoimmune neutropenia of infancy. Blood 62 (1983) 398-400
52. Bussel J., Lalezari P., and Fikrig S. Intravenous treatment with gamma-globulin of autoimmune neutropenia of infancy. J Pediatr 112 (1988) 298-301
53. Bux J., Behrens G., Jaeger G., et al. Diagnosis and clinical course of autoimmune neutropenia in infancy: Analysis of 240 cases. Blood 91 (1998) 181-186
54. Gordon B.G., Kiwanuka J., and Kadushin J. Autoimmune neutropenia and Hodgkin's disease: Successful treatment with intravenous gammaglobulin. Am J Pediatr Hematol Oncol 13 (1991) 164-167
55. Hilgartner M.W., and Bussel J. Use of intravenous gamma globulin for the treatment of autoimmune neutropenia of childhood and autoimmune hemolytic anemia. Am J Med 83 (1987) 25-29
56. Mascarin M., and Ventura A. Anti-Rh(D) immunoglobulin for autoimmune neutropenia of infancy. Acta Paediatr 82 (1993) 142-144
57. Sorensen R.U., and Kallick M.D. Clinical uses of intravenous immune globulin: Immunoglobulin replacement therapy and treatment of autoimmune cytopenias. J Clin Apheresis 4 (1988) 97-103
58. Alliot C., Barrios M., Tabuteau S., et al. Autoimmune cytopenias associated with malignancies and successfully treated with intravenous immune globulins: About two cases. Therapie 55 (2000) 371-374
59. Schoengen A., Fembacher P.M., and Schulz PC. Immunoglobulin therapy for autoimmune neutropenia in Hodgkin's disease. Acta Haematol 94 (1995) 36-38
60. Young N.S., Abkowitz J.L., and Luzzatto L. New insights into the pathophysiology of acquired cytopenias. Hematology (Am Soc Hematol Educ Program) (2000) 18-38
61. Scaradavou A., and Bussel J. Evans syndrome. Results of a pilot study utilizing a multiagent treatment protocol. J Pediatr Hematol Oncol 17 (1995) 290-295
62. Mathew P., Chen G., and Wang W. Evans syndrome: Results of a national survey. J Pediatr Hematol Oncol 19 (1997) 433-437
63. Ucar B., Akgun N., Aydogdu S.D., et al. Treatment of refractory Evans' syndrome with cyclosporine and prednisone. Pediatr Int 41 (1999) 104-107
64. Gombakis N., Trahana M., Athanassiou M., et al. Evans syndrome: Successful management with multi-agent treatment including intermediate-dose intravenous cyclophosphamide. J Pediatr Hematol Oncol 21 (1999) 248-249
65. Chang D.K., Yoo D.H., Kim T.H., et al. Induction of remission with intravenous immunoglobulin and cyclophosphamide in steroid-resistant Evans' syndrome associated with dermatomyositis. Clin Rheumatol 20 (2001) 63-66
66. Muwakkit S., Rachid R., Bazarbachi A., et al. Treatment-resistant infantile Evans syndrome. Pediatr Int 43 (2001) 502-504
67. Muwakkit S., Locatelli F., Abboud M., et al. Report of a child with vitiligo and Evans syndrome. J Pediatr Hematol Oncol 25 (2003) 344-345
68. Petrides P.E., and Hiller E. Autoimmune hemolytic anemia combined with idiopathic thrombocytopenia (Evans syndrome). Sustained remission in a patient following high-dose intravenous gamma-globulin therapy. Clin Investig 70 (1992) 38-39
69. Friedmann A.M., King K.E., Shirey R.S., et al. Fatal autoimmune hemolytic anemia in a child due to warm-reactive immunoglobulin M antibody. J Pediatr Hematol Oncol 20 (1998) 502-505
70. Qureshi S., Zaman S., and Iqbal J. Intravenous immunoglobulin G therapy in Evans syndrome. J Pak Med Assoc 50 (2000) 321-323
71. Bolis S., Marozzi A., Rossini F., et al. High dose intravenous immunoglobulin (IVIgG) in Evans' syndrome. Allergol Immunopathol (Madr) 19 (1991) 186
72. Kaplan C., Murphy M.F., Kroll H., et al. Feto-maternal alloimmune thrombocytopenia: Antenatal therapy with IvIgG and steroids-more questions than answers. Br J Haematol 100 (1998) 62-65
73. Gaddipati S., Berkowitz R.L., Lembet A.A., et al. Initial fetal platelet counts predict the response to intravenous gammaglobulin therapy in fetuses that are affected by PLA1 incompatibility. Am J Obstet Gynecol 185 (2001) 976-980
74. Giers G., Hoch J., Bauer H., et al. Therapy with intravenous immunoglobulin G (ivIgG) during pregnancy for fetal alloimmune (HPA-1a(Zwa)) thrombocytopenic purpura. Prenat Diagn 16 (1996) 495-502
75. Silver R.M., Porter T.F., Branch D.W., et al. Neonatal alloimmune thrombocytopenia: Antenatal management. Am J Obstet Gynecol 182 (2000) 1233-1238
76. Kornfeld I., Wilson R.D., Ballem P., et al. Antenatal invasive and noninvasive management of alloimmune thrombocytopenia. Fetal Diagn Ther 11 (1996) 210-217
77. Bussel J.B., Berkowitz R.L., Lynch L., et al. Antenatal management of alloimmune thrombocytopenia with intravenous gamma-globulin: A randomized trial of the addition of low-dose steroid to intravenous gamma-globulin. Am J Obstet Gynecol 174 (1996) 1414-1423
78. Birchall J.E., Murphy M.F., Kaplan C., et al. European collaborative study of the antenatal management of feto-maternal alloimmune thrombocytopenia. Br J Haematol 122 (2003) 275-288
79. Cordonnier C., Chevret S., Legrand M., et al. Should immunoglobulin therapy be used in allogeneic stem-cell transplantation? A randomized, double-blind, dose effect, placebo-controlled, multicenter trial. Ann Intern Med 139 (2003) 8-18
80. Abdel-Mageed A., Graham-Pole J., Del Rosario M.L., et al. Comparison of two doses of intravenous immunoglobulin after allogeneic bone marrow transplants. Bone Marrow Transplant 23 (1999) 929-932
81. Feinstein L.C., Seidel K., Jocum J., et al. Reduced dose intravenous immunoglobulin does not decrease transplant-related complications in adults given related donor marrow allografts. Biol Blood Marrow Transplant 5 (1999) 369-378
82. Winston D.J., Antin J.H., Wolff S.N., et al. A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation. Bone Marrow Transplant 28 (2001) 187-196
83. Winston D.J., Ho W.G., Bartoni K., et al. Intravenous immunoglobulin and CMV-seronegative blood products for prevention of CMV infection and disease in bone marrow transplant recipients. Bone Marrow Transplant 12 (1993) 283-288
84. Winston D.J., Ho W.G., Lin C.H., et al. Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation. Ann Intern Med 106 (1987) 12-18
85. Zikos P., Van Lint M.T., Lamparelli T., et al. A randomized trial of high dose polyvalent intravenous immunoglobulin (HDIgG) vs. cytomegalovirus (CMV) hyperimmune IgG in allogeneic hemopoietic stem cell transplants (HSCT). Haematologica 83 (1998) 132-137
86. Ruutu T., Ljungman P., Brinch L., et al. No prevention of cytomegalovirus infection by anti-cytomegalovirus hyperimmune globulin in seronegative bone marrow transplant recipients. The Nordic BMT Group. Bone Marrow Transplant 19 (1997) 233-236
87. Bowden R.A., Fisher L.D., Rogers K., et al. Cytomegalovirus (CMV)-specific intravenous immunoglobulin for the prevention of primary CMV infection and disease after marrow transplant. J Infect Dis 164 (1991) 483-487
88. Lum L., Bitonti O., Jin N.R., et al. Intravenous gamma-globulin (IVIG) does not alter immune parameters in a randomized trial after bone-marrow transplantation (BMT). Exp Hematol 22 (1994) 680
89. Pole J.G. Preventing systemic infections with IVIG: A randomized multicenter trial. Bone Marrow Transplant 5 (1990) 132 (suppl 2)
90. Poynton C.H., Jackson S., Fegan C., et al. Use of IgM enriched intravenous immunoglobulin (Pentaglobin) in bone marrow transplantation. Bone Marrow Transplantation 9 (1992) 451-457
91. Sullivan K.M., Storek J., Kopecky K.J., et al. A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-vs.-host disease after marrow transplantation: Clinical outcome and effect on subsequent immune recovery. Biol Blood Marrow Transplant 2 (1996) 44-53
92. Sullivan K.M., Kopecky K.J., Jocom J., et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med 323 (1990) 705-712
93. Wolff S.N., Fay J.W., Herzig R.H., et al. High-dose weekly intravenous immunoglobulin to prevent infections in patients undergoing autologous bone marrow transplantation or severe myelosuppressive therapy. A study of the American Bone Marrow Transplant Group. Ann Intern Med 118 (1993) 937-942
94. Aldan H., and Cordonnier C. Antimicrobial prophylaxis in EBMT centers : A report from the Infectious Diseases Working Party. Bone Marrow Transplant 27 (2001) S202 Suppl 1, abstr
95. American Academy of Pediatrics. Subcommittee on hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics 114 (2004) 297-316
96. Gottstein R., and Cooke R.W. Systematic review of intravenous immunoglobulin in haemolytic disease of the newborn. Arch Dis Child Fetal Neonatal Ed 88 (2003) F6-F10
97. Alcock G.S., and Liley H. Systematic review: Immunoglobulin infusion for isoimmune haemolytic jaundice in neonates. Cochrane Database Syst Rev (2002) CD003313
98. Alpay F., Sarici S.U., Okutan V., et al. High-dose intravenous immunoglobulin therapy in neonatal immune haemolytic jaundice. Acta Paediatr 88 (1999) 216-219
99. Dagoglu T., Ovali F., Samanci N., et al. High-dose intravenous immunoglobulin therapy for rhesus haemolytic disease. J Int Med Res 23 (1995) 264-271
100. Rubo J., Albrecht K., Lasch P., et al. High-dose intravenous immune globulin therapy for hyperbilirubinemia caused by Rh hemolytic disease. J Pediatr 121 (1992) 93-97
101. Woodcock B.E., Walker S., and Adams K. Haemolytic transfusion reaction-Successful attenuation with methylprednisolone and high dose immunoglobulin. Clin Lab Haematol 15 (1993) 59-61
102. Kohan A.I., Niborski R.C., Rey J.A., et al. High-dose intravenous immunoglobulin in non-ABO transfusion incompatibility. Vox Sang 67 (1994) 195-198
103. Cullis J.O., Win N., Dudley J.M., et al. Post-transfusion hyperhaemolysis in a patient with sickle cell disease: Use of steroids and intravenous immunoglobulin to prevent further red cell destruction. Vox Sang 69 (1995) 355-357
104. Gangarossa S., and Lucini N.R. High-dose intravenous immunoglobulin therapy, blood rheology, and sickle cell anemia. Pediatr Hematol Oncol 10 (1993) 377-378
105. Win N., Doughty H., Telfer P., et al. Hyperhemolytic transfusion reaction in sickle cell disease. Transfusion 41 (2001) 323-328
106. Robson W.L., Fick G.H., Jadavji T., et al. The use of intravenous gammaglobulin in the treatment of typical hemolytic uremic syndrome. Pediatr Nephrol 5 (1991) 289-292
107. Sheth K.J., Gill J.C., and Leichter H.E. High-dose intravenous gamma globulin infusions in hemolytic-uremic syndrome: A preliminary report. Am J Dis Child 144 (1990) 268-270
108. Dervenoulas J., Tsirigotis P., Bollas G., et al. Efficacy of intravenous immunoglobulin in the treatment of thrombotic thrombocytopaenic purpura. A study of 44 cases. Acta Haematol 105 (2001) 204-208
109. Centurioni R., Bobbio-Pallavicini E., Porta C., et al. Treatment of thrombotic thrombocytopenic purpura with high-dose immunoglobulins. Results in 17 patients. Italian Cooperative Group for TTP. Haematologica 80 (1995) 325-331
110. Finazzi G., Bellavita P., Falanga A., et al. Inefficacy of intravenous immunoglobulin in patients with low-risk thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome. Am J Hematol 41 (1992) 165-169
111. Warkentin T.E., and Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) 311S-337S (3 Suppl) (Erratum in: Chest 127:416, 2005]
112. Winder A., Shoenfeld Y., Hochman R., et al. High-dose intravenous gamma-globulins for heparin-induced thrombocytopenia: A prompt response. J Clin Immunol 18 (1998) 330-334
113. Grau E., Linares M., Olaso M.A., et al. Heparin-induced thrombocytopenia-response to intravenous immunoglobulin in vivo and in vitro. Am J Hematol 39 (1992) 312-313
114. Perrella O. Idiopathic thrombocytopenic purpura in HIV infection: therapeutic possibilities of intravenous immunoglobulins. J Chemother 2 (1990) 390-393
115. Jahnke L., Applebaum S., Sherman L.A., et al. An evaluation of intravenous immunoglobulin in the treatment of human immunodeficiency virus-associated thrombocytopenia. Transfusion 34 (1994) 759-764
116. Schrappe-Bacher M., Rasokat H., Bauer P., et al. High-dose intravenous immunoglobulins in HIV-1-infected adults with AIDS-related complex and Walter-Reed 5. Vox Sang 59 (1990) 3-14 (Suppl 1)
117. De Simone C., Tzantzoglou S., Santini G., et al. Clinical and immunologic effects of combination therapy with intravenous immunoglobulins and AZT in HIV-infected patients. Immunopharmacol Immunotoxicol 13 (1991) 447-458
118. Majluf-Cruz A., Luna-Castanos G., Huitron S., et al. Usefulness of a low-dose intravenous immunoglobulin regimen for the treatment of thrombocytopenia associated with AIDS. Am J Hematol 59 (1998) 127-132
119. Blanchette V.S., Luke B., Andrew M., et al. A prospective, randomized trial of high-dose intravenous immune globulin G therapy, oral prednisone therapy, and no therapy in childhood acute immune thrombocytopenic purpura. J Pediatr 123 (1993) 989-995
120. Blanchette V. Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura. Lancet 344 (1994) 703-707
121. Duru F., Fisgin T., Yarali N., et al. Clinical course of children with immune thrombocytopenic purpura treated with intravenous immunoglobulin G or megadose methylprednisolone or observed without therapy. Pediatr Hematol Oncol 19 (2002) 219-225
122. Fujisawa K., Iyori H., Ohkawa H., et al. A prospective, randomized trial of conventional, dose-accelerated corticosteroids and intravenous immunoglobulin in children with newly diagnosed idiopathic thrombocytopenic purpura. Int J Hematol 72 (2000) 376-383
123. Imbach P., Wagner H.P., Berchtold W., et al. Intravenous immunoglobulin versus oral corticosteroids in acute immune thrombocytopenic purpura in childhood. Lancet 2 (1985) 464-468
124. Khalifa A.S., Tolba K.A., el Alfy M.S., et al. Idiopathic thrombocytopenic purpura in Egyptian children. Acta Haematol 90 (1993) 125-129
125. Mori P.G., Lanza T., Mancuso G., et al. Treatment of acute idiopathic thrombocytopenic purpura (AITP): Cooperative Italian study group results. Pediatric 5 (1988) 169-178
126. Ozsoylu S., Sayli T.R., and Ozturk G. Oral megadose methylprednisolone versus intravenous immunoglobulin for acute childhood idiopathic thrombocytopenic purpura. Pediatric 10 (1993) 317-321
127. Rosthoj S., Nielsen S., and Pedersen F.K. Randomized trial comparing intravenous immunoglobulin with methylprednisolone pulse therapy in acute idiopathic thrombocytopenic purpura. Danish I.T.P. Study Group. Acta Paediatr 85 (1996) 910-915
128. Warrier I., Bussel J.B., Valdez L., et al. Safety and efficacy of low-dose intravenous immune globulin (IVIG) treatment for infants and children with immune thrombocytopenic purpura. Low-Dose IVIG Study Group. J Pediatr Hematol Oncol 19 (1997) 197-201
129. Tovo P.A., Miniero R., Fiandino G., et al. Fc-depleted vs intact intravenous immunoglobulin in chronic ITP. J Pediatr 105 (1984) 676-677
130. British Committee for Standards in Haematology General Haematology Task Force. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 120 (2003) 574-596
131. Beck C.E., Nathan P.C., Parkin P.C., et al. Corticosteroids versus intravenous immune globulin for the treatment of acute immune thrombocytopenic purpura in children: A systematic review and meta-analysis of randomized controlled trials. J Pediatr 147 (2005) 521-527
132. George J.N., Woolf S.H., Raskob G.E., et al. Idiopathic thrombocytopenic purpura: A practice guideline developed by explicit methods for the American Society of Hematology. Review. Blood 88 (1996) 3-40
133. Godeau B., Chevret S., Varet B., et al. Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: A randomised, multicentre trial. Lancet 359 (2002) 23-29
134. von dem Borne A.E., Vos J.J., Pegels J.G., et al. High dose intravenous methylprednisolone or high dose intravenous gammaglobulin for autoimmune thrombocytopenia. Br Med J (Clin Res Ed) 296 (1988) 249-250
135. Colovic M., Dimitrijevic M., Sonnenburg C., et al. Clinical efficacy and safety of a novel intravenous immunoglobulin preparation in adult chronic ITP. Hematol J 4 (2003) 358-362
136. Godeau B., Lesage S., Divine M., et al. Treatment of adult chronic autoimmune thrombocytopenic purpura with repeated high-dose intravenous immunoglobulin. Blood 82 (1993) 1415-1421
137. Godeau B., Caulier M.T., Decuypere L., et al. Intravenous immunoglobulin for adults with autoimmune thrombocytopenic purpura: Results of a randomized trial comparing 0.5 and 1 g/kg B.W. Br J Haematol 107 (1999) 716-719
138. Wehmeier A. Tolerability and efficacy of 5% versus 10% intravenous immunoglobulin preparation in adult patients with immune thrombocytopenia-a pilot study. Infusionsther Transfusionsmed 23 (1996) 104-108 (Suppl 4)
139. Jacobs P., and Wood L. The comparison of gammaglobulin to steroids in treating adult immune thrombocytopenia. An interim analysis. Blut 59 (1989) 92-95
140. Mueller-Eckhardt C., and Kiefel V. High-dose IgG for post-transfusion purpura-revisited. Blut 57 (1988) 163-167
141. Ningsanond V. Infection associated hemophagocytic syndrome: A report of 50 children. J Med Assoc Thai 83 (2000) 1141-1149
142. Chen J.S., Chang K.C., Cheng C.N., et al. Childhood hemophagocytic syndrome associated with Kikuchi's disease. Haematologica 85 (2000) 998-1000
143. Fort D.W., and Buchanan G.R. Treatment of infection-associated hemophagocytic syndrome with immune globulin. J Pediatr 124 (1994) 332
144. Freeman B., Rathore M.H., Salman E., et al. Intravenously administered immune globulin for the treatment of infection-associated hemophagocytic syndrome. J Pediatr 123 (1993) 479-481
145. Goulder P., Seward D., and Hatton C. Intravenous immunoglobulin in virus associated haemophagocytic syndrome. Arch Dis Child 65 (1990) 1275-1277
146. Chen T.L., Wong W.W., and Chiou T.J. Hemophagocytic syndrome: An unusual manifestation of acute human immunodeficiency virus infection. Int J Hematol 78 (2003) 450-452
147. Gill D.S., Spencer A., and Cobcroft R.G. High-dose gamma-globulin therapy in the reactive haemophagocytic syndrome. Br J Haematol 88 (1994) 204-206
148. Kaneko M., Kuwabara S., Hatakeyama A., et al. Guillain-Barre and virus-associated hemophagocytic syndromes contracted simultaneously following Epstein-Barr viral infection. Neurology 49 (1997) 870-871